selected publications
-
A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia.
Alimentary pharmacology & therapeutics.
2024
Academic Article
GET IT
Times cited: 12 -
Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
Alimentary pharmacology & therapeutics.
2024
Review
GET IT
Times cited: 20 -
Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease.
Alimentary pharmacology & therapeutics.
2024
Academic Article
GET IT
Times cited: 6 -
Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality.
Alimentary pharmacology & therapeutics.
2023
Review
GET IT
Times cited: 20 -
MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-Individual participant data meta-analyses.
Alimentary pharmacology & therapeutics.
2023
Review
GET IT
Times cited: 14 -
Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis.
The lancet. Gastroenterology & hepatology.
2023
Review
GET IT
Times cited: 102 -
Noninvasive tests in the evaluation of nonalcoholic fatty liver disease: A review.
Clinical liver disease.
2023
Review
GET IT
Times cited: 4 -
Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores.
Hepatology communications.
2023
Academic Article
GET IT
Times cited: 28 -
MRI-AST (MAST) Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
2023
Academic Article
GET IT
Times cited: 24 -
Longitudinal Assessment of Bile Duct Loss in Primary Biliary Cholangitis.
The American journal of gastroenterology.
2022
Academic Article
GET IT
Times cited: 5 -
Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis.
Hepatology (Baltimore, Md.).
2022
Academic Article
GET IT
Times cited: 39 -
MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
Journal of hepatology.
2021
Academic Article
GET IT
Times cited: 127 -
Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes.
Digestive diseases and sciences.
2021
Academic Article
GET IT
Times cited: 18 - Sex differences in age at wait-list registration for liver transplantation with nonalcoholic steatohepatitis as primary indication. Clinical transplantation. 2020 Letter GET IT
-
Driving Nonalcoholic Steatohepatitis Forward Using the FibroScan Aspartate Aminotransferase Score, But Obey the Traffic Lights.
Hepatology (Baltimore, Md.).
2020
Comment
GET IT
Times cited: 13